Insight Molecular Diagnostics Return on Tangible Equity 2014-2025 | IMDX
Insight Molecular Diagnostics Return On Tangible Equity Historical Data | |||
---|---|---|---|
Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
2025-03-31 | $-0.06B | $0.00B | 210.71% |
2024-12-31 | $-0.06B | $-0.03B | 159.48% |
2024-09-30 | $-0.04B | $-0.05B | 108.64% |
2024-06-30 | $-0.04B | $-0.03B | 113.43% |
2024-03-31 | $-0.04B | $-0.05B | 145.13% |
2023-12-31 | $-0.03B | $-0.04B | 133.33% |
2023-09-30 | $-0.06B | $-0.02B | 292.31% |
2023-06-30 | $-0.06B | $-0.01B | 269.66% |
2023-03-31 | $-0.06B | $-0.02B | 237.62% |
2022-12-31 | $-0.07B | $-0.03B | 217.91% |
2022-09-30 | $-0.06B | $-0.03B | 209.84% |
2022-06-30 | $-0.07B | $-0.03B | 261.54% |
2022-03-31 | $-0.07B | $-0.05B | 297.87% |
2021-12-31 | $-0.06B | $-0.02B | -3657.14% |
2021-09-30 | $-0.03B | $-0.01B | -438.71% |
2021-06-30 | $-0.03B | $-0.02B | -203.77% |
2021-03-31 | $-0.03B | $0.05B | -125.30% |
2020-12-31 | $-0.03B | $0.01B | -260.87% |
2020-09-30 | $-0.03B | $0.01B | -188.24% |
2020-06-30 | $-0.03B | $0.02B | -137.93% |
2020-03-31 | $-0.03B | $0.01B | -98.11% |
2019-12-31 | $-0.02B | $0.03B | -66.67% |
2019-09-30 | $-0.02B | $0.03B | -73.08% |
2019-06-30 | $-0.02B | $0.03B | -81.93% |
2019-03-31 | $-0.02B | $0.04B | -121.43% |
2018-12-31 | $-0.02B | $0.00B | -261.54% |
2018-09-30 | $-0.02B | $0.01B | -237.04% |
2018-06-30 | $-0.02B | $0.01B | -307.69% |
2018-03-31 | $-0.02B | $0.01B | -316.67% |
2017-12-31 | $-0.02B | $0.00B | -333.33% |
2017-09-30 | $-0.02B | $0.01B | -262.07% |
2017-06-30 | $-0.02B | $0.01B | -176.47% |
2017-03-31 | $-0.01B | $0.01B | -175.00% |
2016-12-31 | $-0.01B | $0.01B | -160.00% |
2016-09-30 | $-0.01B | $0.01B | -173.33% |
2016-06-30 | $-0.01B | $0.00B | -266.67% |
2016-03-31 | $-0.01B | $0.01B | -266.67% |
2015-12-31 | $-0.01B | $0.01B | -355.56% |
Sector | Industry | Market Cap | Revenue |
---|---|---|---|
Medical | Medical Information Systems | $0.069B | $0.002B |
Insight Molecular Diagnostics Inc. is a pioneering diagnostics technology company. Insight Molecular Diagnostics Inc., formerly known as Oncocyte Corporation, is based in NASHVILLE, Tenn. |
Stock Name | Country | Market Cap | PE Ratio |
---|---|---|---|
Veeva Systems (VEEV) | United States | $44.935B | 57.17 |
Tempus AI (TEM) | United States | $12.393B | 0.00 |
Doximity (DOCS) | United States | $11.901B | 52.95 |
Hims & Hers Health (HIMS) | United States | $10.549B | 87.28 |
IRhythm Technologies (IRTC) | United States | $5.208B | 0.00 |
Hinge Health (HNGE) | United States | $4.462B | 0.00 |
Privia Health (PRVA) | United States | $2.542B | 188.27 |
Inspire Medical Systems (INSP) | United States | $2.501B | 36.77 |
Phreesia (PHR) | United States | $1.667B | 0.00 |
Enovis (ENOV) | United States | $1.647B | 8.71 |
10x Genomics (TXG) | United States | $1.630B | 0.00 |
Omnicell (OMCL) | United States | $1.446B | 27.85 |
Schrodinger (SDGR) | United States | $1.427B | 0.00 |
Azenta (AZTA) | United States | $1.402B | 61.18 |
Clover Health Investments (CLOV) | United States | $1.317B | 0.00 |
Claritev (CTEV) | United States | $1.117B | 0.00 |
Evolent Health (EVH) | United States | $1.035B | 0.00 |
Fulgent Genetics (FLGT) | United States | $0.665B | 0.00 |
Zepp Health (ZEPP) | Netherlands | $0.509B | 0.00 |
Veradigm (MDRX) | United States | $0.498B | 0.00 |
Standard BioTools (LAB) | United States | $0.463B | 0.00 |
Talkspace (TALK) | United States | $0.424B | 126.50 |
Carlsmed (CARL) | $0.370B | 0.00 | |
Butterfly Network (BFLY) | United States | $0.355B | 0.00 |
TruBridge (TBRG) | United States | $0.287B | 50.40 |
Nyxoah SA (NYXH) | Belgium | $0.232B | 0.00 |
Outset Medical (OM) | United States | $0.229B | 0.00 |
SOPHiA GENETICS SA (SOPH) | Switzerland | $0.222B | 0.00 |
Health Catalyst (HCAT) | United States | $0.206B | 0.00 |
KORU Medical Systems (KRMD) | United States | $0.190B | 0.00 |
CapsoVision (CV) | United States | $0.186B | 0.00 |
MDxHealth SA (MDXH) | Belgium | $0.134B | 0.00 |
American Well (AMWL) | United States | $0.117B | 0.00 |
CareCloud (CCLD) | United States | $0.108B | 4.92 |
EUDA Health Holdings (EUDA) | Singapore | $0.097B | 0.00 |
ImmunoPrecise Antibodies (IPA) | Canada | $0.093B | 0.00 |
Pulmonx (LUNG) | United States | $0.062B | 0.00 |
111 (YI) | China | $0.057B | 0.00 |
P3 Health Partners (PIII) | United States | $0.050B | 0.00 |
HeartBeam (BEAT) | United States | $0.038B | 0.00 |
Zhongchao (ZCMD) | China | $0.024B | 0.00 |
Precipio (PRPO) | United States | $0.024B | 0.00 |
Healthcare Triangle (HCTI) | United States | $0.019B | 0.00 |
Bullfrog AI Holdings (BFRG) | United States | $0.013B | 0.00 |
Predictive Oncology (POAI) | United States | $0.009B | 0.00 |
HeartSciences (HSCS) | United States | $0.008B | 0.00 |
Strata Skin Sciences (SSKN) | United States | $0.008B | 0.00 |
Mobile-health Network Solutions (MNDR) | Singapore | $0.006B | 0.00 |
MSP Recovery (MSPR) | United States | $0.005B | 0.00 |
Movano (MOVE) | United States | $0.004B | 0.00 |
Evaxion - (EVAX) | Denmark | $0.004B | 0.00 |
Tivic Health Systems (TIVC) | United States | $0.004B | 0.00 |
PROFUSA (PFSA) | United States | $0.003B | 0.00 |
Future Health ESG (FHLT) | United States | $0.000B | 0.00 |